Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSVUC Pilot: Magtrace for SLN Detection in Vulvar Cancer
NCT06273501Enrolling by invitation
- Sponsor
- Sahlgrenska University Hospital
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Open-label, single-arm trial of Magtrace in vulvar squamous cell carcinoma (VSCC), sponsored by Sahlgrenska University Hospital. Primary endpoint: Sentinel lymph node identification at 30 days. Started Mar 2022; status: enrolling by invitation.
02
Drugs
Magtrace
03
Conditions
vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on NCT06273501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06273501.